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a  b  s  t  r  a  c  t
Therapeutic  monoclonal  antibodies  represent  one  of the fastest  growing  segments  in  the  pharmaceutical
market.  The  growth  of  the  segment  has  necessitated  development  of  new  efﬁcient  and  cost  saving  plat-
forms for  the preparation  and  analysis  of early  candidates  for faster  and  better  antibody  selection  and
characterization.  We  report  on  a new  integrated  platform  for  automated  harvesting  of  whole  unclariﬁed
cell-culture  broths,  followed  by  in-line  tandem  afﬁnity-capture,  pH  neutralization  and  size-exclusion
chromatography  of recombinant  antibodies  expressed  transiently  in  mammalian  human  embryonic  kid-
ney 293T-cells  at the  1-L scale.  The  system  consists  of two  bench-top  chromatography  instruments
connected  to a central  unit  with  eight  disposable  ﬁltration  devices  used  for loading  and  ﬁltering  the  cell
cultures.  The  staggered  parallel  multi-step  conﬁguration  of the  system  allows  unattended  processing  of
eight samples  in  less  than  24  h. The  system  was  validated  with  a random  panel  of 45 whole-cell  culture
broths  containing  recombinant  antibodies  in the early  proﬁling  phase.  The  results  showed  that  the  overall
performances  of the preparative  automated  system  were  higher  compared  to the conventional  down-
stream  process  including  manual  harvesting  and  puriﬁcation.  The  mean  recovery  of puriﬁed  material
from  the  culture-broth  was  66.7%,  representing  a 20%  increase  compared  to that  of the  manual  process.
Moreover,  the  automated  process  reduced  by 3-fold  the  amount  of  residual  aggregates  in the  puriﬁed
antibody  fractions,  indicating  that the  automated  system  allows  the cost-efﬁcient  and timely  preparation
of  antibodies  in  the  20–200  mg  range,  and  covers  the  requirements  for early  in vitro  and  in  vivo proﬁling
and  formulation  of  these  drug  candidates.
© 2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license. Introduction
Therapeutic monoclonal antibodies (mAbs) and antibody-
elated molecules such as immunoglobulin Fc-fusion proteins
epresent a fast growing class of therapeutics, with nearly 50 prod-
cts approved or pending registration in the US and the EU [1].
he development of these new biologics requires effective discov-
ry platforms including high throughput antibody production and
haracterization. Powerful display methods such as phage display,
sed in combination with large combinatorial antibody libraries
llow the rapid generation of a large panel of molecules [2]. In this
arly selection phase, when dealing with hundreds to thousands
f candidates, only a few g up to a couple of mg  of antibod-
es prepared on robotic platforms are required to carry out the
∗ Corresponding author. Tel.: +41 61 324 9570/+41 61 696 3781.
E-mail address: jm.schlaeppi@vtxmail.ch (J.-M. Schlaeppi).
ttp://dx.doi.org/10.1016/j.chroma.2015.09.040
021-9673/© 2015 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
necessary biological and biophysical analysis [3]. Major develop-
ments in high throughput (HT) technology for producing a large
panel of recombinant proteins have been driven initially by struc-
tural genomics and proteomics initiatives [4–6]. Back to back fully
automated robotic installations for mammalian expression and
puriﬁcation of thousands of recombinant secreted proteins at the
sub-mg scale have been reported [7]. In parallel, important progress
has been made in the development of novel micro-bioreactors
for HT small-scale parallel expression to support process devel-
opment [8], and has been validated with small-scale disposable
reactors up to culture volumes of 250 mL  [9]. The downstream
processing has relied mainly on modiﬁed liquid-handling sys-
tems able to carry out afﬁnity-capture puriﬁcation of recombinant
antibodies or tagged-proteins [10–12]. Later on during the gener-
ation of therapeutic antibodies, the selection focuses on the 20–50
remaining candidates having shown the required biological and
developability properties. Their further proﬁling, including bio-
physical screens and formulation studies, yet also conﬁrming their
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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iological efﬁcacy in rodents or other animals, will require larger
mounts, usually in the 50–200 mg  range. Whereas many of the
nalytical platforms used for proﬁling these candidates have been
ptimized towards automation and higher throughput [13], the
pstream and downstream preparative steps to produce sufﬁcient
mounts of materials rely largely on low throughput manual or
emi-automated processes only. Upstream, a cost-effective and fast
ay to produce these quantities is to express them as recombi-
ant antibodies transiently in mammalian cells such as human
mbryonic kidney (HEK)-293 cells. This is done usually in 1-L roller-
ottles or in 10–100 L Wave bioreactors for gram amounts [14].
ownstream, the puriﬁcation is done mainly by afﬁnity capture
AC) chromatography such as protein-A, followed by one or several
olishing steps. To reduce bottlenecks in puriﬁcation, several sys-
ems based on modiﬁed bench-top chromatography instruments
ave increased the throughput by integrating automated mul-
iple chromatographic steps, using intermediate pool collection
etween each chromatography step [15–18]. Recent improvements
ave been achieved by using a direct ﬂow-through system with
n-line neutralization [19] or by combining up to four puriﬁca-
ion columns [20]. Another way to increase throughput, yet keeping
he advantages offered by benchtop chromatography instruments
uch as UV monitoring, is to include a dedicated auto-sampler for
nattended tandem chromatography on the ÄKTATM platform. The
ystem is optimally designed to accommodate clariﬁed sample-
olumes up to 50 mL  [21]. In this report, we have dealt with our
ownstream bottlenecks often encountered in preparing enough
aterial for extended proﬁling of therapeutic antibody candidates,
y building a bench-scale platform, which integrates the harvest-
ng step and the puriﬁcation in the automated process. Up to eight
-L unclariﬁed HEK293 cell culture-broths (CB) containing recom-
inant antibodies are clariﬁed in-line by disposable ﬁlters, before
eing puriﬁed by tandem puriﬁcation, avoiding time-consuming
anual harvesting steps. The whole process runs in 19 h including
he complete cleaning in place (CIP) and column re-equilibration
o avoid sample cross-contamination, allowing the puriﬁcation of
0 cell-cultures per week with a minimum of attendance. The
utomated system results in an approximatively 4-fold increase
n throughput compared to the conventional downstream pro-
ess relying on manual steps, yet provides material of comparable
uality. The system includes additional features such as air bub-
les and constant pressure monitoring, in-line pH neutralization
fter the capture step and efﬁcient aggregate removal by adding
n in-line ﬁltration step before the size-exclusion chromatography
SEC).
. Materials and methods
.1. Automated instrumentation
Automated harvesting, puriﬁcation and CIP were performed
n two bench-top chromatography instruments ÄKTATM pure
5 M,  equipped with two system pumps capable of a ﬂow rate
f 25 mL/min and with both the U9-M triple variable wavelength
nd the U9-L ﬁxed wavelength UV monitors (GE Healthcare Life
ciences, Uppsala, Sweden). Each instrument held the AC and
EC columns for the two-step puriﬁcation, and performed iden-
ical operations. The two instruments were connected to a central
nit containing eight disposable ﬁltration devices, the two sam-
le pumps S9 and sample inlet valves. The whole system was
ontrolled by the UNICORNTM software version 6.4 (GE Health-
are Life Sciences). The instruments operated at room temperature
RT), only the two fraction collectors F9-C were kept at 7 ◦C in a
ustom-made three-door cooling cabinet (Koch-Kaelte AG, Appen-
ell, Switzerland).Fig. 1. Overview of the main steps of the automated process.
2.2. Automated unclariﬁed sample application, tandem
puriﬁcation and cleaning-in-place – a process overview
A brief overview of the automated process is shown in Fig. 1.
Operations were phased and staggered to process eight 1-L unclar-
iﬁed CB in 19 h. Up to four bottles were connected to the
sample-inlet valve of the corresponding chromatography instru-
ment. Two  samples were loaded in parallel at a ﬂow rate of
6 mL/min through individual single-use ﬁltration devices ULTATM
Disc GF 47 mm,  5.0 m pore size (GE Healthcare Life Sciences),
to remove cells and cell debris before being puriﬁed in-line
using tandem chromatography. MAbs were captured by protein-
A afﬁnity chromatography on two interconnected 5-mL HiTrapTM
MabSelectTM SuReTM columns equilibrated with Dulbecco phos-
phate buffered saline pH 7.3 (dPBS). This afﬁnity medium was
chosen for its high mAb  binding and speciﬁcity properties and its
alkali tolerance for efﬁcient CIP. We  used two interconnected 5-
mL columns to ensure enough binding capacity. After loading, the
HiTrap columns were washed with 15 column volumes (CV) of dPBS
followed by a one-step elution at 5 mL/min with 50 mM Na-OAc
buffer (Merck, Darmstadt, Germany). When the A280 nm exceeded
a threshold value of 400 mAU, the in-line pH neutralization of
the eluted protein fraction was  triggered by applying a gradi-
ent of 320 mM Tris base (Sigma–Aldrich, Steinheim, Germany). In
parallel, the A600 nm was monitored for indication of light scat-
tering due to the presence of aggregates. The samples were then
passed through a ﬁlter Filtopur S, 0.45 m at 5 mL/min (Sarstedt,
Numbrecht, Germany) for potential aggregate removal and were
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hen applied to the SEC column HiLoadTM 26/600 SuperdexTM 200
rep grade (320 mL  column) equilibrated with dPBS. The Superdex
edium was chosen for its fractionation range and low non-speciﬁc
nteractions. Collection of the mAb  monomeric peak was triggered,
hen the UV signal exceeded a given threshold value. The auto-
ated process also included a CIP of both the AC and SEC columns
o avoid any cross-contamination. The AC columns were cleaned
ith 0.5 M NaOH at 5 mL/min, for 15 min  (using the sample pump),
nd then re-equilibrated with dPBS. The SEC columns were cleaned
ith a 60 mL  pulse of 0.5 M NaOH at 4 mL/min (15 min  contact time)
sing the buffer pump, followed by equilibration with dPBS until
he pH monitored at the SEC column outlet was stable for 10 min.
.3. Generation of recombinant mAbs by transient expression in
EK293 cells
The human and mouse mAbs were cloned into CMV-promoter-
riven expression plasmids for mammalian cell expression. The
Abs (mostly IgG1) were subsequently produced by transient
ransfection in HEK293-T at a 1-L scale in roller bottles, essen-
ially as described previously [14]. The cells in proprietary M11V3
edium were transfected with a DNA:PEI ratio of 1:3 (Polyscience,
arrington, USA). The cells were fed with the same volume of
x-Cell VPro medium (Sigma–Aldrich, St.Louis, USA) and culti-
ated at 37 ◦C, 7.5 rpm, 5% CO2 for 7 days. Our standard 2-step
uriﬁcation was done by transferring the unclariﬁed feeds into
00 mL  centrifugation tubes (Corning Incorporated, Oneonta, USA)
nd centrifuged for 15 min  at 4500 rpm followed by clariﬁcation
hrough a 0.22 m sterile ﬁlter (Millipore, Zug, Switzerland). The
upernatants were puriﬁed on ÄKTA explorer at 7 ◦C, on HiTrap
olumns as described in Section 2.2. The mAbs were eluted with
ight CV of 50 mM Na-citrate, 90 mM NaCl, pH 3.2. Fractions were
ollected, neutralized to pH 7.0 and concentrated to a volume of
 mL  before being further puriﬁed on a 120-mL HiLoad 16/600
uperdexTM 200 pg column equilibrated with dPBS. Protein concen-
ration of the puriﬁed antibody samples was measured by recording
he absorbance at 280 nm using an UV/vis spectral-photometer
anodrop 1000 (Thermo Scientiﬁc, Switzerland) and using the mAb
peciﬁc extinction coefﬁcient. The ﬁnal recoveries were calculated
s the percentage of mAb  measured in the puriﬁed fractions by
anodrop to that measured in the unclariﬁed CB by Protein-A-HPLC
see Section 2.4).
.4. Titer determination by Protein A-HPLC – in process control
IPC)
Concentration determinations of antibody-containing super-
atants were performed on a 1260 Inﬁnity HPLC system (Agilent
echnologies, Basel, Switzerland) holding an HPLC cartridge packed
ith 62.5 L of MabSelect Sure material (GE Healthcare Life Sci-
nces). Running buffers were 50 mM H3BO3, 200 mM Na2SO4 pH
.5 (buffer A) and pH 2.5 (buffer B). The ﬂow rate was 0.75 mL/min
nd 0.1 mL  of supernatant was injected into the protein A col-
mn and rinsed with buffer A for 5.5 min. The bound antibody
as eluted with buffer B for 2.5 min. The 215 nm UV trace was
onitored and the elution peak area was used for quantita-
ion.
.5. Analytics of the puriﬁed materials
.5.1. Aggregation determination by SEC
The aggregation level of puriﬁed mAbs was measured by SECn an Agilent 1290 Inﬁnity system equipped with a Superdex
00 10/300 GL column (GE Healthcare Life Sciences). The sam-
le (50 L) was loaded on the column equilibrated with dPBS at
H 7.3. The ﬂow rate was 0.5 mL/min and the protein absorbancer. A 1418 (2015) 103–109 105
was measured at 230 nm.  The percentage of aggregates was cal-
culated from the peak area at different retention times. Peaks
which did not exhibit baseline separation were resolved by con-
structing lines at the point of peak intersection orthogonal to the
absorbance baseline. Fractional concentrations were calculated by
dividing individual peak areas by the sum of peak areas. The column
was calibrated using an internal IgG standard previously validated
to be 98% monomeric on a comparable SEC column coupled to a
multi-angle light scattering detector [13].
2.5.2. Sodium dodecyl sulfate polyacrylamide gel-electrophoresis
(SDS–PAGE)
SDS–PAGE was performed with 4–20% Mini-Protean® TGXTM
Gels and Precision Plus Dual Color standards (Bio-Rad, Hercules,
USA). Two g of sample was loaded on the gel and run in
Tris/Glycine/SDS buffer according to the manufacturer’s instruc-
tions.
2.5.3. Mass determination by mass spectrometry
Mass determination by mass spectrometry was done by LC–MS
using a Waters Acquity UPLC system coupled to a Waters Q-TOF
Premier Mass Spectrometer. Around 5 g of antibody was injected
at a ﬂow rate of 0.1 mL/min onto a MassPrep micro-desalting
cartridge (Waters, 186002785) heated at 80 ◦C, and eluted with
a 12-min gradient (2–90%) of water/acetonitrile containing 0.1%
formic acid.
2.5.4. Endotoxin detection
Endotoxin levels were measured in puriﬁed mAb samples by
the Limulus Amebocyte Lysate (LAL) assay, using Endosafe dispos-
able test cartridges and the PTSTM Portable Test System (Charles
River Laboratories, France). The cartridges were adjusted to RT and
samples were diluted to a minimum concentration of 0.01 mg/mL
and were added into the cartridges followed by spectrophotometric
measurement.
3. Results and discussion
3.1. Instrumental platform
A picture of the complete system and the ﬂowchart depicting the
overall automated process are shown in the supporting informa-
tion Figs. S1 and S2, respectively. The process consists of a number
of generic protein preparation steps, which were integrated and
optimized with the goal of obtaining endotoxin-free monomeric
IgG (>95%) with recoveries at least comparable to those of our
standard downstream procedures, and allowing us to prepare unat-
tended, eight different 1-L cell-culture bottles in less than 24 h. The
two, connected bench-top chromatography systems were identi-
cally equipped and conﬁgured, to perform identical yet in staggered
phased operations. Optimization of the expression conditions, size
and type of the ﬁltration and chromatographic media, ﬂow-rate,
elution and pH neutralization buffers were performed as part of the
system set-up. Below, the critical aspects of the system conﬁgura-
tion are highlighted (ﬂow paths and connected parts are illustrated
for only one of the two  instruments).
3.1.1. Sample application
Each of four 1-L cell culture bottles, containing different mAbs
expressed transiently in HEK293-T cells, were connected to an inlet
valve containing an integrated air sensor to control a safe and
complete sample loading. Feedback from the air sensor ended the
sample application, when completed. The sample pump, located
downstream of the inlet valve, moved the sample through a second
valve with an integrated pressure sensor (pre-ﬁlter) and through
one of four 5 m nominal pore size single-use ﬁlters and back
106 F. Holenstein et al. / J. Chromatogr. A 1418 (2015) 103–109
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ample) on AC-unit #2. (B) By-passing AC-unit #1 and mAb  adsorption on AC-unit #
espectively. The grey ﬂowpath is inactive. The ﬁlled circles represent valves. Only 
hrough the same valve and a post-ﬁlter pressure sensor. Delta
ressure was registered to track ﬁlter status and detects potential
logging. The sample was then applied to the protein-A column.
he sample application part of the system’s ﬂow path, as described
bove, was driven by the sample pump.
.1.2. Dual-ﬂow for parallel afﬁnity capture and elution
The two chromatography puriﬁcation steps (AC and SEC) were
erformed in tandem with no intermediate peak storage. Both
hromatography steps were thus operated at the same ﬂow rate. A
ow cell for A280 nm monitoring was placed after each column out-
et. Each chromatography system had two AC-units, consisting each
f two interconnected 5-mL HiTrap columns to provide enough
Ab  binding capacity. Indeed, we have observed that loading the
olumn below its maximum binding capacity prevents potential
ggregation of the antibodies (Holenstein unpublished observa-
ions). A key to high productivity was that different operations. (A) Parallel mAb  adsorption on the AC-unit #1 and mAb  elution (from another
 different active ﬂow paths are designated with broken and solid lines and arrows,
tive valve ports are indicated.
were carried out simultaneously on the two AC-units. The liquid
ﬂow through one of the AC-units was  driven by the sample pump
while the ﬂow through of the second AC-unit was  driven by the
buffer pump (Fig. S2). This enabled parallel mAb adsorption on one
AC-unit and elution of another sample on the other (Fig. 2A). This
conﬁguration also enabled one AC-unit to be by-passed (e.g., during
CIP of the SEC column) while the sample was  loaded on the other
AC-unit (Fig. 2B). Also, it enabled sample loading on one AC-unit
while the other was  being cleaned (not shown).
3.1.3. Neutralization and aggregate removal
In order to minimize mAb  exposure to acidic pH, an in-line neu-
tralization step was  included after elution from the AC-unit. Both
AC-units were connected to an outlet valve, and an alkaline neutral-
ization buffer was  introduced in the ﬂow path immediately after
the valve. To secure a smooth pH transition, the alkaline buffer
was introduced by a separate pump as a gradient, and was added
F. Holenstein et al. / J. Chromatogr. A 1418 (2015) 103–109 107
Fig. 3. Overall timelines for processing eight unclariﬁed cell-culture broths in 19 h.
Fig. 4. Result overview of one representative sample puriﬁcation showing: (A) chromatogram of the automated in-line tandem afﬁnity-capture (AC) and size-exclusion
chromatography (SEC) as described in Section 2.2. Both absorbance at 280 nm (mAU, blue) and 600 nm (mAu, red) are shown. The recovery was 75.4%, and the purity was
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in Fig. 3. To allow for ﬂexibility regarding the number of samples,9.9%;  (B) P monitoring (mPa) during the in-line ﬁltration of the unclariﬁed cell-cu
nd  reduced samples; lane 2, molecular weight markers. The mAb  titer in the cell-cu
nto the system ﬂow in an active mixer (Fig. S3). The neutralized
Ab  fraction then passed through a ﬂow cell for simultaneous
onitoring of A280 nm (for protein quantitation) and A600 nm (for
ndication of light scattering due to aggregation). An in-line ﬁltra-
ion step (0.45 m nominal pore size) was used to remove larger
ggregates, if any, before the sample was applied to the SEC col-
mn. A separate ﬁlter was used for each mAb  sample. The ﬂow
ath through the 0.45 m ﬁlter was opened when elution from
he AC-column was started, and it was closed, thus by-passing the
lter, (Fig. S3) when the UV peak signal was below a set thresh-
ld.oth; (C) SDS–PAGE of the collected antibody SEC fractions; lanes 1 and 3, unreduced
broth was 107.2 mg/L and the cell density at time of harvest was 2.8 × 106 cells/mL.
3.1.4. Phasing and programming
A single, optimized and automated puriﬁcation cycle (including
sample loading, ﬁltration, AC, SEC, CIP and column equilibration)
took 7.5 h. In order to be able to achieve 40 such cycles within
a working week, using two  chromatography instruments, it was
not only essential to perform different operations in parallel on
each chromatography instrument as described above, but also to
phase the puriﬁcations. The staggered phasing scheme is shownand to avoid unnecessary complexity with respect to programming,
ﬁve different UNICORN methods were developed for performing
108 F. Holenstein et al. / J. Chromatogr. A 1418 (2015) 103–109
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Fig. 6. Scatter plot representation and mean of the percentage of recovery of 45
feeds run by the automated process compared to 102 feeds run by the conventionalrations was  subjected to the automated tandem puriﬁcation. The ﬁnal recovery
orresponds to the percentage of mAb  measured in the puriﬁed fractions by Nano-
rop (A280 nm) to that initially loaded on the system.
he puriﬁcation of four samples. The methods were arranged in a
ethod queue and were executed sequentially.
.2. Validation of the automated system
.2.1. Performances and reliability
The reliability of the automated instrumentation was  tested by
epeated loading of unclariﬁed CBs or spiked samples at different
ntibody concentrations. The intra- and inter-run variations were
.6% (n = 23) and 2.1% (n = 19) respectively, with an average mAb
ecovery of 80%, indicative of good reproducibility of the auto-
ated tandem chromatography. A representative chromatogram
f the automated harvest and puriﬁcation of one unclariﬁed sample
s shown in Fig. 4A. The one-step elution is started after washing
he HiTrap column and when the absorbance at 280 nm exceeds
 threshold value of 400 mAU, the peak collection and in-line pH
eutralization of the eluted protein fraction is triggered by apply-
ng a gradient of 320 mM Tris base. The sample is passed through
he Filtopur ﬁlter for potential aggregate removal and is applied
o the SEC column. In parallel, the A600 nm is monitored for indi-
ation of light scattering from potential aggregates, which in the
xample is negligible. In parallel, the A600 nm monitored the pres-
nce of potential aggregates, which is in our example is negligible.
he AC peak collection ends when the A280 nm returns to 600 mAU.
ollection of the puriﬁed mAb  monomeric peak after SEC chro-
atography is triggered likewise, when the UV signal exceeded a
iven threshold value. Fig. 4B shows the pressure monitoring dur-
ng the pre-capture ﬁltration, in-line AC loading and ﬁlter washing
riggered by the air sensors. The Delta pressure (P) is monitored
o track ﬁlter status, an increase in pressure indicating ﬁlter clog-
ing. Fig. 4C shows the purity of the ﬁnal puriﬁed mAb  analyzed
y SDS–PAGE. Transient expression in mammalian cells such as
EK293-T results after 7 days of cultivation in an average cell den-
ity of 3.0 × 106 cells/mL, with around 86% cell-viability. Under
hese conditions, little build-up of pressure during the cell-culture
ltration was observed and did not interfere with the completion
f the clariﬁcation, even with those antibodies having aggregation
ssues. Antibody titers obtained by transient expression ranged
etween 15 and 200 mg/L of cell-culture. Therefore, we  selected
he sizes of the AC and SEC columns according to these speciﬁca-
ions. As shown in Fig. 5, the best recoveries were indeed, obtained
ith antibody concentrations between 25 and 300 mg/L. Samples
ith titers lower than 25 mg/L gave poor recoveries and were less
uitable for the automated set-up. Reducing the column sizes bymanual process. (T-test analysis, p < 0.0001). Recovery is calculated as the percentage
of  mAb  measured in the puriﬁed fractions by Nanodrop (A280 nm) to that measured in
the  unclariﬁed cell-culture broths by in-process control (IPC) as described in Section
2.4.
2-fold, namely to a single 5-mL HiTrap column and a 120-mL SEC
column, in addition to an optimization of the separation conditions,
would be an alternative for samples with low titers.
3.2.2. Comparison between automated and manual downstream
process
The performances of the automated harvesting and tandem
puriﬁcation were compared to those of our manual process includ-
ing manual harvesting and 2-step puriﬁcation. A random panel
of 45 unclariﬁed CBs was run on the system and the recover-
ies were compared to those of 102 antibodies prepared by the
manual process. As shown in Fig. 6, the results indicated that the
recoveries were signiﬁcantly higher with the automated process
compared to the manual one, the mean recoveries being 66.7% and
46.6% respectively (p < 0.0001). The quality of the puriﬁed antibod-
ies was  measured by various analytical methods, including SEC for
aggregation level, SDS–PAGE for overall purity (Fig. 4C), LC–MS for
integrity and identity, and LAL assay for endotoxin level. Overall
the automated process resulted in samples with the same quality
as measured by SDS–PAGE and LC–MS. The comparison by ESI-TOF
mass spectrometry of a representative antibody puriﬁed by con-
ventional and automated methods is shown in the supporting Figs.
S4–S9. Fully comparable mass spectra were measured. Glycoforms
represented the main source of microheterogeneity. The average
residual content of aggregates was  reduced in the automated pro-
cess (0.7%) compared to the manual one (2.3%). During our manual
process, some problematic antibodies tend to precipitate upon pH
neutralization of the protein-A fractions resulting in low recov-
eries. The standardized, gentle and fast in-line pH neutralization
seems to reduce these losses. Indeed, by comparing the recover-
ies of eight culture-broths split between both the manual and the
automated processes, we  found the same trend towards higher
recoveries with the automated process (Table 1). The comprehen-
sive end-product quality control analysis showed that the quality
of the material prepared by the 2-step automated puriﬁcation was
as comparable to that of the material puriﬁed by conventional man-
ual harvesting and puriﬁcation (Table 1). Overall, by increasing the
throughput without reducing the quality of the ﬁnal products, the
automated process is a valuable approach to improve the produc-
tivity of the antibody-selection process. Noteworthy was the low
endotoxin level measured in the ﬁnal puriﬁed samples, despite run-
ning the automated process at RT, in contrast to the manual process
run entirely at cold temperature. Indeed, all values remained well
below the threshold of 5 EU/mg of mAb, required for most preclin-
ical animal applications [22].
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Table  1
Comparison between automated and manual process of the quality of puriﬁed mAbs.
Automated process Manual process
Recoverya [%] Aggregates [%] Monomeric [%] Endotoxin [EU/mg] Recoverya [%] Aggregates [%] Monomeric [%] Endotoxin [EU/mg]
mAb  1 55.4 0.3 99.7 1.4 53.3 1.1 98.9 0.6
mAb  2 66 0.3 99.3 <0.8 61.6 1.1 98.9 <0.5
mAb  3 80.6 0.4 99.6 <0.5 68.4 0.2 99.8 <0.3
mAb  4 59.3 0.1 99.9 nd 42.8 1.1 88.3 nd
mAb  5 37.0 0.1 99.9 nd 27.9 0.4 99.6 nd
mAb  6 71.1 0.3 99.7 <0.4 48.9 0.3 99.7 <0.3
mAb  7 67.6 0.1 91.8 <0.4 40.8 0.1 91.2 <0.3
mAb  8 85.3 0.9 99.1 <0.7 63.5 1.7 98.3 <0.5
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a The ﬁnal recovery represents the percentage of mAb  measured in the puriﬁed f
n  Section 2.4.
. Conclusion
We  have set-up an automated system for in-line harvesting and
uriﬁcation of 1-L antibody containing cell-culture broths to cover
ur needs for the efﬁcient preparation of therapeutic antibody can-
idates in the early in vitro and in vivo proﬁling phase. By integrating
he time-consuming harvesting step in the automated process, we
ould reduce our downstream bottlenecks that we  experienced,
hen covering many requests for antibodies in the 50–200 mg
ange. Indeed, to remain cost effective, we have concentrated our
fforts on the downstream part, leaving limited manual steps for
he upstream transient transfection and cell cultivation. A back to
ack fully automated solution at this volume scale would imply
 very complex and space-intensive robotic installation, proba-
ly necessitating specially trained operators. The ﬂexibility of our
ystem made of bench-top instruments equipped with standard
omponents and software should be operational for all kinds of
ecreted recombinant proteins puriﬁed by any capture step, such as
c-proteins or else. Furthermore, we conclude that the automated
rocess eliminates subjective user decisions, minimizing waste and
otential contamination due to intermediate pooling and fraction
ollection, and thereby increases process yields and reproducibility.
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